Beam Therapeutics Inc. Payments to Acquire Held-to-maturity Securities
Beam Therapeutics Inc. (BEAM) reported Payments to Acquire Held-to-maturity Securities of $289.22 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-11.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireHeldToMaturitySecurities · last filed 2021-05-11
- Beam Therapeutics Inc. payments to acquire held-to-maturity securities for the quarter ending 2021-03-31 was $289.22M, a 145.69% increase year-over-year.
- Beam Therapeutics Inc. payments to acquire held-to-maturity securities for the quarter ending 2020-12-31 was $114.52M, a 522.85% increase year-over-year.
- Beam Therapeutics Inc. payments to acquire held-to-maturity securities for the quarter ending 2020-09-30 was $31.14M, a 36.07% increase year-over-year.
- Beam Therapeutics Inc. payments to acquire held-to-maturity securities for the quarter ending 2020-06-30 was $18.24M.
- Beam Therapeutics Inc. payments to acquire held-to-maturity securities for fiscal 2020 was $281.61M, a 117.03% increase from fiscal 2019.
- Beam Therapeutics Inc. payments to acquire held-to-maturity securities for fiscal 2019 was $129.76M.
| Period end | Payments to Acquire Held-to-maturity Securities 3 month | Payments to Acquire Held-to-maturity Securities 6 month | Payments to Acquire Held-to-maturity Securities 9 month | Payments to Acquire Held-to-maturity Securities 12 month |
|---|---|---|---|---|
| 2021-03-31 | $289.22M 10-Q · filed 2021-05-11 | $403.74M derived: sum of 2 quarters · filed 2021-05-11 | $434.87M derived: sum of 3 quarters · filed 2021-05-11 | $453.11M derived: sum of 4 quarters · filed 2021-05-11 |
| 2020-12-31 | $114.52M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $145.65M derived: sum of 2 quarters · filed 2021-03-15 | $163.89M derived: sum of 3 quarters · filed 2021-03-15 | $281.61M 10-K · filed 2021-03-15 |
| 2020-09-30 | $31.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $49.38M derived: sum of 2 quarters · filed 2020-11-10 | $167.09M 10-Q · filed 2020-11-10 | $185.48M derived: sum of 4 quarters · filed 2021-05-11 |
| 2020-06-30 | $18.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $135.96M 10-Q · filed 2020-08-12 | $154.34M derived: sum of 3 quarters · filed 2021-05-11 | $177.23M derived: sum of 4 quarters · filed 2021-05-11 |
| 2020-03-31 | $117.72M 10-Q · filed 2021-05-11 | $136.10M derived: sum of 2 quarters · filed 2021-05-11 | $158.99M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $18.39M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $41.27M derived: sum of 2 quarters · filed 2021-03-15 | $129.76M 10-K · filed 2021-03-15 | |
| 2019-09-30 | $22.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $111.37M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $88.49M 10-Q · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |